Ireland - English - HPRA (Health Products Regulatory Authority)

g.l. pharma gmbh - potassium iodide - tablet - 65 milligram(s) - antidotes; potassium iodide

Malta - English - Medicines Authority

g.l. pharma gmbh schlossplatz 1, 8502 lannach, austria - potassium iodide - tablet - potassium iodide 65 mg - all other therapeutic products

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

hameln pharma ltd - potassium iodide - oral tablet - 65mg

European Union - English - EMA (European Medicines Agency)

les laboratoires servier - pegaspargase - precursor cell lymphoblastic leukemia-lymphoma - antineoplastic agents, - oncaspar is indicated as a component of antineoplastic combination therapy in acute lymphoblastic leukaemia (all) in paediatric patients from birth to 18 years, and adult patients.,

Ireland - English - HPRA (Health Products Regulatory Authority)

b. braun avitum ag - sodium chloride ph.eur.; sodium hydrogen carbonate; calcium chloride dihydrate; magnesium chloride hexahydrate; glucose monohydrate - solution for haemofiltration - . - hemofiltrates

Ireland - English - HPRA (Health Products Regulatory Authority)

b. braun avitum ag - sodium chloride ph.eur.; sodium hydrogen carbonate; calcium chloride dihydrate; magnesium chloride hexahydrate; glucose monohydrate; potassium chloride - solution for haemofiltration - 2 millimole(s)/litre - hemofiltrates

Ireland - English - HPRA (Health Products Regulatory Authority)

b. braun avitum ag - sodium chloride ph.eur.; sodium hydrogen carbonate; calcium chloride dihydrate; magnesium chloride hexahydrate; glucose monohydrate; potassium chloride - solution for haemofiltration - 4 millimole(s)/litre - hemofiltrates

United States - English - NLM (National Library of Medicine)

cardinal health - potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152) - potassium chloride 149 mg in 1 ml - potassium chloride for injection concentrate, usp is indicated in the treatment of potassium deficiency states when oral replacement is not feasible. potassium chloride for injection concentrate, usp is contraindicated in diseases where high potassium levels may be encountered, and in patients with hyperkalemia, renal failure and in conditions in which potassium retention is present.

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - potassium phosphate, monobasic (unii: 4j9fj0hl51) (phosphate ion - unii:nk08v8k8hr), potassium phosphate, dibasic (unii: ci71s98n1z) (phosphate ion - unii:nk08v8k8hr) - potassium phosphate, monobasic 224 mg in 1 ml - potassium phosphates injection, usp is indicated as a source of phosphate, for addition to large volume intravenous fluids to prevent or correct hypophosphatemia in patients with restricted or no oral intake. it is also useful as an additive for preparing specific intravenous fluid formulas when the needs of the patient cannot be met by standard electrolyte of nutrient solutions. potassium phosphates is contraindicated in diseases where high potassium, high phosphate or low calcium levels may be encountered.

United States - English - NLM (National Library of Medicine)

ncs healthcare of ky, inc dba vangard labs - potassium chloride (unii: 660yq98i10) (chloride ion - unii:q32zn48698) - potassium chloride 750 mg - because of reports of intestinal and gastric ulceration and bleeding with controlledrelease potassium chloride preparations, these drugs should be reserved for those patients who cannot tolerate or refuse to take liquid or effervescent potassium preparations or for patients in whom there is a problem of compliance with these preparations. 1. for the treatment of patients with hypokalemia with or without metabolic alkalosis, in digitalis intoxications, and in patients with hypokalemic familial periodic paralysis. if hypokalemia is the result of diuretic therapy, consideration should be given to the use of a lower dose of diuretic, which may be sufficient without leading to hypokalemia. 2. for the prevention of hypokalemia in patients who would be at particular risk if hypokalemia were to develop e.g., digitalized patients or patients with significant cardiac arrhythmias, hepatic cirrhosis with ascites, states of aldosterone excess with normal renal function, potassium-losing nephropathy, and certain diarrhea